Pretransplant Therapy of Chronic Phase Patients (n = 152)
| Randomized Therapy . | . | Received Therapy . | . |
|---|---|---|---|
| Hydroxyurea | n = 46 | Hydroxyurea | n = 44* |
| IFN ± CHT† | n = 2 | ||
| Busulfan | n = 25 | Busulfan | n = 19* |
| IFN ± CHT | n = 5 | ||
| Hydroxyurea | n = 1 | ||
| IFN ± CHT | n = 81 | IFN ± CHT | n = 79 |
| Hydroxyurea | n = 2 |
| Randomized Therapy . | . | Received Therapy . | . |
|---|---|---|---|
| Hydroxyurea | n = 46 | Hydroxyurea | n = 44* |
| IFN ± CHT† | n = 2 | ||
| Busulfan | n = 25 | Busulfan | n = 19* |
| IFN ± CHT | n = 5 | ||
| Hydroxyurea | n = 1 | ||
| IFN ± CHT | n = 81 | IFN ± CHT | n = 79 |
| Hydroxyurea | n = 2 |
| Duration and Dosage of Received Therapy in Chronic Phase Patients, Median (range) . | |||
|---|---|---|---|
| . | Duration of Therapy . | Total Dosage . | Daily Dose . |
| Hydroxyurea (n = 47‡) | 1.2 (0.2-4.5) yr | 453 (36-4,046) g | 1.4 (0.11-2.5) g |
| Busulfan (n = 192-153) | 0.5 (0.1-1.7) yr | 271 (92-1,720) mg | 2.1 (0.8-8.4) mg |
| Interferon α ± CHT (n = 86) | 1.2 (0.1-4.7) yr | 2,246 (225-13,887) × 106 IU | 5.9 (0.84-13.6) × 106 IU |
| Duration and Dosage of Received Therapy in Chronic Phase Patients, Median (range) . | |||
|---|---|---|---|
| . | Duration of Therapy . | Total Dosage . | Daily Dose . |
| Hydroxyurea (n = 47‡) | 1.2 (0.2-4.5) yr | 453 (36-4,046) g | 1.4 (0.11-2.5) g |
| Busulfan (n = 192-153) | 0.5 (0.1-1.7) yr | 271 (92-1,720) mg | 2.1 (0.8-8.4) mg |
| Interferon α ± CHT (n = 86) | 1.2 (0.1-4.7) yr | 2,246 (225-13,887) × 106 IU | 5.9 (0.84-13.6) × 106 IU |
Median interval from IFN discontinuation to BMT: 50 (1-2,029) days.
In 1 hydroxyurea and 1 busulfan patient information on therapy is incomplete. Because there was no indication that randomized therapy had not been given, they were counted as treated with randomized therapy.
CHT, chemotherapy.
1 patient also received busulfan.
12 patients also received hydroxyurea.